Gridley D S, Mackensen D G, Slater J B, Moyers M F, Slater J M
Department of Microbiology & Molecular Genetics, Loma Linda University School of Medicine, CA 92350, USA.
J Immunother Emphasis Tumor Immunol. 1995 May;17(4):229-37. doi: 10.1097/00002371-199505000-00005.
A major limitation of radiolabeled monoclonal antibodies (MAbs) for cancer imaging and therapy is their low accumulation within solid tumors. We, and others, have previously shown that pretreatment of a tumor mass with gamma radiation can increase the level of radiolabeled MAb at the tumor site. Unlike that of conventional radiation, the dose distribution of protons allows for increasing the dose to the cancer volume while reducing the normal tissue dose. The Proton Radiation Therapy Facility at LLUMC treats patients and conducts research. In this study, we sought to determine if preirradiation with proton beam can enhance the localization of radiolabeled MAb within xenotransplanted human colon tumors. T380 colon tumors, implanted s.c. into athymic mice, were subjected to proton irradiation (10 Gy, single dose) when mean tumor volume was 125-135 mm3/group. 111In-ZCE025, a murine MAb directed against carcinoembryonic antigen, was injected i.p. 2 h later, and biodistribution studies were performed 38 h thereafter. Animals irradiated with 60Co and given either 111In-ZCE025 or 111In-MOPC21, an irrelevant MAb, served as controls. The mean percentage of injected radioactivity localized within tumors was highest in the group treated with protons + 111In-ZCE025 when expressed on a per gram basis (%ID/g = 19.3). Somewhat unexpectedly, higher radioactivity was also noted in the normal tissues of these animals compared to other groups. The mean %ID/g tumor values for those given 60Co + 111In-ZCE025 or the antibody alone were 12.5 and 9.0. Our data show that preirradiation of solid tumors increases the localization of tumor-specific radiolabeled MAb at the tumor site.(ABSTRACT TRUNCATED AT 250 WORDS)
放射性标记单克隆抗体(MAb)用于癌症成像和治疗的一个主要限制是它们在实体瘤内的低蓄积。我们及其他研究人员先前已表明,用γ射线对肿瘤块进行预处理可提高放射性标记单克隆抗体在肿瘤部位的水平。与传统辐射不同,质子的剂量分布可在增加癌组织剂量的同时降低正常组织剂量。LLUMC的质子放射治疗设施为患者提供治疗并开展研究。在本研究中,我们试图确定质子束预照射是否能增强放射性标记单克隆抗体在异种移植的人结肠肿瘤内的定位。当平均肿瘤体积为125 - 135 mm³/组时,将T380结肠肿瘤皮下植入无胸腺小鼠体内,并对其进行质子照射(10 Gy,单次剂量)。2小时后腹腔注射针对癌胚抗原的鼠单克隆抗体111In - ZCE025,此后38小时进行生物分布研究。用60Co照射并给予111In - ZCE025或无关单克隆抗体111In - MOPC21的动物作为对照。以每克为基础表示时,接受质子 + 111In - ZCE025治疗的组中,肿瘤内定位的注入放射性平均百分比最高(%ID/g = 19.3)。 somewhat unexpectedly(这个词在提供的文本中有误,原词可能是“Somewhat unexpectedly”,意思是“ somewhat unexpectedly(有点出乎意料地)”)与其他组相比,这些动物的正常组织中也观察到较高的放射性。给予60Co + 111In - ZCE025或仅给予抗体的组的平均肿瘤%ID/g值分别为12.5和9.0。我们的数据表明,实体瘤的预照射可增加肿瘤特异性放射性标记单克隆抗体在肿瘤部位的定位。(摘要截断于250字)